We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENX:EURONEXT PARISEuronext NV Analysis

Data as of 2026-03-13 - not real-time

€139.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Euronext trades at €139, comfortably above its 20‑day (≈€134.6) and 200‑day (≈€133.1) moving averages, indicating short‑term momentum, yet the MACD histogram is negative and the signal line is bearish, while volume is trending lower and the RSI sits at 62, suggesting the rally may be losing steam near the €142.4 resistance. The stock’s trailing P/E of 22 is well above the industry average of 16, and the DCF‑derived fair value of €130.2 places the current price slightly premium, though forward earnings are expected to rise to €8.52, compressing the forward P/E to 16 and supporting the analyst consensus “Buy” with median target €150.
A voluntary share‑exchange offer to acquire all shares of Hellenic Exchanges expands ENX’s footprint in Southern Europe, complementing its already diversified pan‑European platform, while a pending lawsuit from Italy’s CDP introduces moderate regulatory risk. The company delivers a solid 35% profit margin, a 46% dividend payout yielding 2.1%, and a healthy cash position that underpins dividend sustainability, positioning ENX as a blend of growth and value with attractive upside potential despite heightened volatility.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram and decreasing volume
  • Price approaching technical resistance
  • RSI indicating overbought conditions

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Successful acquisition of Hellenic Exchanges expanding market reach
  • Forward earnings growth compressing forward P/E to 16
  • Analyst median target of €150 implying ~8% upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable dividend payout with 46% payout ratio
  • Strong operating margins and profit margins above 30%
  • Diversified European footprint reducing single‑country exposure

Key Metrics & Analysis

Financial Health

Revenue Growth9.80%
Profit Margin35.35%
P/E Ratio22.1
ROE15.11%
ROA0.19%
Debt/Equity71.83
P/B Ratio3.1
Op. Cash Flow€812.1M
Free Cash Flow€740.8M
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI62.4
Support€120.00
Resistance€142.40
MA 20€134.55
MA 50€126.40
MA 200€133.11
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair Value€130.23
Target Price€147.94
Upside/Downside6.43%
GradeFair
TypeBlend
Dividend Yield2.10%

Risk Assessment

Beta0.14
Volatility29.70%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.